Osteometer BioTech A/S Announces Issuance of First US Patent for its Collagen Breakdown Technology.Business Editors & Health/Medical Writers BIOWIRE2K COPENHAGEN, Denmark--(BW HealthWire)--Sept. 29, 2000 Osteometer BioTech A/S (www.osteobio.com) today announced the issuance on August 22, 2000, of U.S. Patent No. 6,107,047 covering key aspects of its technology for estimation of collagen breakdown. The patent discloses improved methods for estimating bone resorption Bone resorption is the process by which osteoclasts break down bone and release the minerals, resulting in a transfer of calcium from bone fluid to the blood. The osteoclasts are multi-nucleated cells that contain numerous mitochondria and lysosomes. by measuring fragments of type I collagen containing certain age-modified (isomerised) peptide sequences Peptide sequence or amino acid sequence is the order in which amino acid residues, connected by peptide bonds, lie in the chain in Peptides and Proteins. . Any isomerised type I collagen fragment, including those originating from the C- or the N-terminal telopeptides (CTX CTX Context (Management; Tandem) CTX Centex Corporation (stock symbol) CTX Centrex CTX Cyclophosphamide CTX Corporate Trade Exchange CTX Cytoxan CTX Cholera Toxin CTX Clinical Trial Exemption and NTX NTX N-Telopeptide Cross-Links (bone resorption marker) NTX Navy Teletypewriter Exchange NTX Nt Extended NTX Network Terminal Accelerator ), are covered by the patent, and this is a key feature of the Serum CrossLaps test marketed by the Company. "This is a major milestone for our Company," says Klaus Eldrup-Jorgensen, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Osteometer BioTech. "Together with other patents expected to be granted later this year, our patent portfolio protects the essential elements needed in a sensitive and specific test for bone resorption based on serum measurements. Scientific studies published during the last two years have demonstrated the clinical potential of our technology in monitoring anti-resorptive therapies, and this acknowledgement from the Patent & Trademark Office will support our efforts to position our serum test in the forefront of biochemical testing Biochemical testing Measuring the amount or activity of a particular enzyme or protein in a sample of blood or urine or other tissue from the body. Mentioned in: Von Willebrand Disease for osteoporosis." Osteometer BioTech is engaged in the discovery and development of tests to be used in the management of osteoporosis, arthritis and cancer. All three medical areas are characterised by intense pharmaceutical research and the requirements for medical intervention as well as tools for diagnosis and monitoring are high. The Company has already launched several unique products and through alliances with leading diagnostic companies are making these available world wide. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion